2026-01-06 - Analysis Report
Here's a breakdown of the Teladoc Health (TDOC) stock analysis, incorporating the data you provided:

**0) Report in English with Simple Analysis**

**1) Return Rate Comparison**

*   **TDOC Company Overview:** Teladoc Health Inc. is a telehealth and virtual healthcare company providing on-demand and scheduled medical consultations.
*   **TDOC Cumulative Return:** -64.46%
*   **S&P 500 (VOO) Cumulative Return:** 91.00%
*   **Divergence:**  Current: -155.5, Relative Divergence: 0.7

**Analysis:**

*   TDOC has significantly underperformed the S&P 500.  A negative cumulative return of -64.46% indicates a substantial loss for investors over the period being considered. The S&P 500, by contrast, has generated a strong positive return of 91.00%.
*   The divergence of -155.5 highlights the stark difference in performance.
*   The relative divergence of 0.7 suggests that the current divergence is near the lower end of its historical range. However, given the negative return, this simply means the situation could have been even worse.

**Alpha, Beta Analysis**

| Year       | CAGR     | MDD  | Alpha    | Beta  | Cap(B) |
|------------|----------|------|----------|-------|--------|
| 2016-2018  | 74.0%   | 52.9% | 71.0%   | 1.7   | 9.1    |
| 2017-2019  | 119.0%  | 52.9% | 101.0%  | 1.8   | 15.3   |
| 2018-2020  | 87.0%   | 52.9% | 66.0%   | 0.7   | 36.6   |
| 2019-2021  | -84.0%  | 60.6% | -127.0% | 0.5   | 16.8   |
| 2020-2022  | -246.0% | 83.0% | -244.0% | 0.8   | 4.3    |
| 2021-2023  | -302.0% | 83.0% | -303.0% | 1.9   | 4.0    |
| 2022-2024  | -87.0%  | 72.3% | -107.0% | 1.9   | 1.7    |
| 2023-2025  | -34.0%  | 65.6% | -96.0%  | 1.7   | 1.3    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  The CAGR shows a dramatic shift from strong positive growth in earlier periods to substantial negative growth in recent years.
*   **MDD (Maximum Drawdown):**  The MDD figures are high, indicating significant potential losses for investors at various points.  The MDD has been consistently high.
*   **Alpha:** Alpha measures the stock's performance relative to the market. The overwhelmingly negative alpha values from 2019 onward indicate that TDOC has consistently underperformed its benchmark, even considering its beta.
*   **Beta:** Beta measures volatility compared to the market.  A beta around 1 suggests volatility similar to the market. The beta values have fluctuated, but they are generally around 1. However, the recent Beta is increasing, so it means that fluctuation is getting higher.
*   **Cap(B) (Market Capitalization):** The market capitalization has decreased drastically over time, reflecting investor concerns and the decline in stock price.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 7.05
*   **Last Market Data:** Price: 7.28, Previous Close: 7.05, Change: 3.26%
*   **5-day SMA:** 7.02
*   **20-day SMA:** 7.33
*   **60-day SMA:** 7.76

**Analysis:**

*   The stock is currently trading below its 20-day and 60-day moving averages, suggesting a downtrend. The 5-day SMA is close to the current price.
*   The recent price increase of 3.26% is positive, however it needs to be substantiated with positive indicators.

**3) RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 27.56 (Oversold)
*   **PPO:** -0.32 (Below Zero)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (133 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.7 (+): Short-term Increase
*   **Expected Return (%):** -9726.1%

**Analysis:**

*   The MRI of 0.8 suggests the stock falls into the "Medium Investment" risk category.
*   The RSI of 27.56 indicates that the stock may be oversold and potentially poised for a rebound.
*   The PPO value suggests the stock is in a downtrend.
*   The recent change in relative divergence suggests a short-term upward movement.
*   The extremely negative "Expected Return" should be considered with caution, as the number looks to be extreme. The fact that the expected return is so low indicates a highly pessimistic outlook for the stock's long-term performance.

**4) Recent News & Significant Events:**

*   **Key themes from the news headlines:**  Valuation concerns, comparisons with competitors (HIMS), potential advantages from price action, and analysis of the recent share price rebound. The articles suggest mixed sentiment, with some questioning Teladoc's value proposition compared to alternatives.

**4-2) Analyst Opinions**

*   **Consensus:** Neutral (No key indicated)
*   **Target Price (avg/high/low):** 9.15 / 12.00 / 7.00

**Analysis:**

*   The analyst consensus is neutral, which suggests analysts are not strongly recommending buying or selling the stock.
*   The average target price of $9.15 indicates a potential upside of about 27% from the current price (7.28). However, there are high and low target prices, which means that different analysts' opinions diverge.

**5) Recent Earnings Analysis**

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-10-30 | -0.28  | 0.63 B$ |
| 2025-07-30 | -0.19  | 0.63 B$ |
| 2025-05-01 | -0.53  | 0.63 B$ |
| 2024-10-31 | -0.19  | 0.64 B$ |
| 2025-10-30 | -0.19  | 0.64 B$ |

**Analysis:**

*   Teladoc has not been profitable in recent quarters. All EPS figures are negative.
*   Revenue has remained relatively stable around $0.63-0.64 billion.
*   The recurring negative EPS suggests challenges in cost management or slower than expected growth.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.63B    | 70.12%        |
| 2025-06-30   | $0.63B    | 69.85%        |
| 2025-03-31   | $0.63B    | 68.73%        |
| 2024-12-31   | $0.64B    | 70.50%        |
| 2024-09-30   | $0.64B    | 71.94%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $1.39B    | -3.56%    |
| 2025-06-30   | $1.42B    | -2.30%    |
| 2025-03-31   | $1.43B    | -6.52%    |
| 2024-12-31   | $1.49B    | -3.25%    |
| 2024-09-30   | $1.51B    | -2.21%    |

**Analysis:**

*   **Revenue:** Revenue has been consistent, staying around $0.63-$0.64 billion per quarter.
*   **Profit Margin:** Profit margins are high, indicating efficiency in managing the costs of goods and services sold. However, these high profit margins are not translating into overall profitability due to operating expenses and other factors.
*   **Equity:** Equity is declining, suggesting potential financial strain or inefficient capital management.
*   **ROE (Return on Equity):** ROE is consistently negative, reflecting the company's inability to generate profit from shareholders' investments.

**7) Comprehensive Analysis**

Teladoc Health Inc. (TDOC) presents a mixed picture:

*   **Negative Performance:** TDOC has severely underperformed the S&P 500, with significantly negative cumulative returns, driven by high volatility and a decreasing Market Capitalization.
*   **Financial Concerns:**  The company is not currently profitable (negative EPS and ROE), even though profit margins on revenue appear strong. Declining equity raises additional concerns.
*   **Technical Indicators:** RSI indicates that the stock may be oversold and potentially poised for a rebound in short term.
*   **Analyst Sentiment:** Analysts are neutral, but the average target price suggests potential upside, although analyst target ranges do vary.
*   **News and Events:**  Recent news suggests a focus on valuation, comparison with competitors, and analyzing the recent rebound in share price.

**In conclusion:** TDOC's current situation is precarious. While there may be short-term trading opportunities based on technical indicators or news events, the company's underlying financial performance needs significant improvement to justify a long-term investment. The high profit margin in the financial statement is positive, but it needs to be translated into other positive indicators.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.